[HTML][HTML] Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1 …
Chimeric antigen receptor (CAR)‐T cell therapies have improved the outcome for many
patients with relapsed or refractory aggressive B‐cell lymphomas. In 2017, axicabtagene …
patients with relapsed or refractory aggressive B‐cell lymphomas. In 2017, axicabtagene …
[HTML][HTML] A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …
[HTML][HTML] Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …
[HTML][HTML] Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma
MR Bishop, M Dickinson, D Purtill… - … England Journal of …, 2022 - Mass Medical Soc
Background Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
SS Neelapu, CA Jacobson, A Ghobadi… - Blood, The Journal …, 2023 - ashpublications.org
Abstract In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene
ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy …
ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy …
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm …
SJ Schuster, CS Tam, P Borchmann, N Worel… - The Lancet …, 2021 - thelancet.com
Background In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an
autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall …
autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall …
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell–related
adverse event and remains poorly understood. In this multicenter analysis, we studied …
adverse event and remains poorly understood. In this multicenter analysis, we studied …
[HTML][HTML] Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States
CA Jacobson, FL Locke, L Ma, J Asubonteng… - … and cellular therapy, 2022 - Elsevier
Axicabtagene ciloleucel (axi-cel) is a standard-of-care for patients with relapsed or refractory
(r/r) large B cell lymphoma who have received 2 or more lines of prior therapy. Patients …
(r/r) large B cell lymphoma who have received 2 or more lines of prior therapy. Patients …